REGN•benzinga•
FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion
Summary
FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga